Volume 11, Issue 4 (6-2013)                   IJRM 2013, 11(4): 285-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afrakhteh M, Mahdavi A, Beyhaghi H, Moradi A, Gity S, Zafarghandi S et al . The prevalence of Chlamydia trachomatis in patients who remained symptomatic after completion of sexually transmitted infection treatment. IJRM 2013; 11 (4) :285-0
URL: http://ijrm.ir/article-1-415-en.html
1- Department of Obstetrics and Gynecology, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Obstetrics and Gynecology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran , atossa_mahdavi@yahoo.com
3- Center for Clinical Excellence, Taleghani Hopital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Department of Obstetrics and Gynecology, Mahdieh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (2468 Views)
Background: Sexually transmitted infections (STIs) are among the most common causes of illness in the world and have far-reaching health, economic and social consequences for many countries. Failure to diagnose and treat STIs at an early stage may result in serious complications and sequels.
Objective: This study aimed to determine the prevalence of Chlamydia trachomatis infection in patients who remain symptomatic after completion of their first episode of treatment for STI.
Materials and Methods: We conducted a cross-sectional study on 49 patients suffering from symptoms or signs of sexually transmitted infections despite their first complete anti STI treatment. Conducting physical exam and smear preparation from vaginal discharge, diagnosis was confirmed by Polymerase chain reaction (PCR) method on every patient’s first-voided urine sample.
Results: Among the etiologic factors investigated in this study, Chlamydia was reported in 17 patients. Trichomoniasis, Candidiasis, Gonorrhea and nonspecific germs were next organisms with 11, 9, 6 and 6 patients, respectively. Sixteen specimens were PCR positive (32.65%), while 33 patients had negative PCR results (67.34%) for Chlamydia trachomatis.
Conclusion: Gonorrheal infection was the most prevalent infection in patients with completed treatment (6/10), which must be remembered in patients follow ups, because this prevalence warrants empirical therapy for Gonorrheain similar clinical conditions. Chlamydia trachomatis was the responsible organism in approximately a quarter of patients (17/75) who despite their full compliance on anti-Chlamydial treatment still suffered from signs and symptoms of STI. This rate also recommends empirical therapy for Chlamydia trachomatis in the similar clinical signs and symptoms.
Full-Text [PDF 434 kb]   (635 Downloads) |   |   Full-Text (HTML)  (561 Views)  
Type of Study: Original Article |

References
1. Creighton S, Tenant M, Taylor CB, Miller R, Low N. Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean? Int J STD AIDS 2003; 14: 109-113.
2. Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. Lancet 2006; 368: 2001-2016. [DOI:10.1016/S0140-6736(06)69482-8]
3. CDC Recommendations for prevention and management of Chlamydia trachomatis infections. MMWR Recomm Rep 1993; 42: 1-39.
4. Institute of Medicine, Committee of Prevention and Control of Sexually Transmitted Diseases In: Eng TR, Butler WT, editors. The hidden epidemic: Confronting sexually transmitted diseases. Washington, DC: National Academy Press, 1997.
5. Cates W, Wasserheit JN. Genital chlamydial infections: Epidemiology and reproductive sequels. Am J Obstet Gynecol 1991; 164: 1771-1781. [DOI:10.1016/0002-9378(91)90559-A]
6. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva, Switzerland, 2003.
7. Brunham RC, Paavonen J, Stevens CE, Kiviat N, Kuo CC, Critchlow CW, Holmes KK. Mucopurulent cervicitis- The ignored counterpart in women of urethritis in men. N Engl J Med 1984; 311: 1-6. [DOI:10.1056/NEJM198407053110101]
8. McCormack WM, Alpert S, McComb DE, Nichols RL, Semine DZ, Zinner SH. Fifteen month follow-up study of women infected with Chlamydia trachomatis. N Engl J Med 1979; 300: 123-125. [DOI:10.1056/NEJM197901183000305]
9. Bolan G, Ehrhardt AA, Wasserheit JN. Gender perspectives and STDs In: Holmes KK, Sparling PF, Mårdh PA, et al. Sexually transmitted diseases, 3rd Ed. New York: McGraw-Hill Inc; 1999: 117-127.
10. Miller WC. Screening for Chlamydial Infection: A Model Program Based on Prevalence. Sex Transm Dis 1998; 25: 201-210. [DOI:10.1097/00007435-199804000-00005]
11. Afrakhteh M, Beyhaghi H, Moradi A, Hosseini SJ, Mahdavi A, Giti S, et al. Sexually Transmitted Infections in Tehran. J Fam Reprod Health 2008; 2: 123-128.
12. World Health Organization. Prevention and control of sexually transmitted infections: draft global strategy. Fifty-Ninth World Health Assembly; 2006.
13. Taylor-Robinson D. Evaluation and comparison of tests to diagnose Chlamydia trachomatis genital infections. Hum Reprod 1997; 12 (Suppl.): 113-120.
14. Watson EJ, Templeton A, Russell I, Paavonen J, Mardh P, Stray A, et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002; 51: 1021-1031. [DOI:10.1099/0022-1317-51-12-1021]
15. Ferrero DV, Meyers HN, Schultz DE, Willis SA. Performance of the Gen-Probe AMPLIFIED Chlamydia trachomatis Assay in detecting Chlamydia trachomatis in endocervical and urine specimens from women and urethral and urine specimens from men attending sexually transmitted disease and family planning clinics. J Clin Microbiol 1998; 36: 3230-3233.
16. Sellors J, Howard M, Pickard L, Jang D, Mahony J, Chernesky M. Chlamydia cervicitis; testing the practice guidelines for presumptive diagnosis. Canad Med Assoc J 1998; 13: 41-46.
17. Centers for Disease Control and Prevention (CDC). Chlamydia screening among sexually active young female enrollees of health plans-United States, 1999- 2001. MMWR Morb Mortal Wkly Rep 2004; 53: 983-5.
18. Cates W Jr, Wasserheit JN. Genital Chlamydial infections: epidemicology and reproductive sequeale. Am J Obstet Gynecol 1991; 164: 1771-1781. [DOI:10.1016/0002-9378(91)90559-A]
19. Gerbase AC, Rowley JT, Heymann DH, Berkley SF, Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998; 74 (Suppl.): S12-16.
20. Ghazal-Aswad S, Badrinath P, Osman N, Abdul-Khaliq S, Mc Ilvenny S, Sidky I. Prevalence of Chlamydia trachomatis infection among women in a Middle Eastern community. BMC Womens Health 2004; 27: 3-8. [DOI:10.1186/1472-6874-4-3]
21. Rassjo E B, Kambugu F, Tumwesigye M N, Tenywa T, Darj E. Prevalence of sexually transmitted infections among adolescents in Kampala, Uganda, and theoretical models for improving syndromic management. J Adolesc Health 2006; 38: 213-221. [DOI:10.1016/j.jadohealth.2004.10.011]
22. Levidiotou S, Vrioni G, Papadogeorgaki H, Avdeliodi K, Kada H, Kaparos G, et al. Chlamydia trachomatis infections in Greece: first prevalence study using nucleic acid amplification tests. Eur J Clin Microbiol Infect Dis 2005; 24: 207-213. [DOI:10.1007/s10096-005-1296-8]
23. Berg E, Benson DM, Haraszkiewicz P, Grieb J, McDonald J. High Prevalence of Sexually Transmitted Disease in Women with Urinary Infections. Acad Emerg Med 1996; 3: 1030-1034. [DOI:10.1111/j.1553-2712.1996.tb03349.x]
24. Chamani Tabriz L, Jeddi Tehrani M, Mosavi Jarrahi A, Zeraati H, Ghasemi J, Asgari S, et al. The prevalence of Chlamydia trachomatis infection by molecular analysis of urine samples in women attending OB & GYN clinics in Tehran. J Reroduction and Infertility 2006; 7: 234-242.
25. Fallah F, Kazemi B, Goudarzi H, Badami N, Doostdar F, Ehteda A, et al. Detection of Chlamydia trachomatis from urine specimens by PCR in women with cervicitis. Iran J Public Health 2005; 34: 20-26.
26. Badami N, Salari MH. Rate of Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in infertile females and control group. Iran J Public Health 2001; 30: 57-60.
27. Salari MH, Badami N. The rate of Chlamydia trachomatis, mycoplasma hominis and ureaplasma urealyticum in females with habitual abortion and its compareson with control group. Acta Medica Iranica 2002; 4: 79-82.
28. Zaeimi Yazdi J, Khorramizadeh MR, Badami N, Kazemi B, Aminharati F, Eftekhar Z, et al. Comparative assessment of chlamydia trachomatis infection in Iranian women with cervicitis: A cross-sectional study. Iran J Public Health 2006; 35: 69-75.
29. Samarbafzadeh A, Razi MT, Kelishadi M. Prevalence of C. trachomatis Infection among Ahvaz Females with Vaginal Discharge. J Fertil Steril 2007; 1: 19-22.
30. Chamani L, Tehrani MJ, Akhondi MM, Mosavi A, Zeraati H, Ghasemi J, et al. Chlamydia trachomatis prevalence in Iranian women attending obstetrics and gynecology clinics. Pak J Biol Sci 2007, 10: 4490-4494.
31. Bakhtiari A, Firoozi A. Chlamydia trachomatis infection in women attending health centers in Babol: prevalence and risk factors. East Mediterranean Health J 2007; 13: 1124-1131. [DOI:10.26719/2007.13.5.1124]
32. Jenab A, Roghanian R, Golbang N, Golbang P, Chamani-Tabriz L. Comparison of three methods of DNA extraction in endocervical specimens for Chlamydia trachomatis infection by spectrophotometry, agarose gel, and PCR. Arch Immunol Ther Exp 2010; 58: 227-234. [DOI:10.1007/s00005-010-0076-z]
33. Adams SL, Thompson Da. Inability to follow up ED patients by telephone: there must be 50 ways to leave your number. Acad Emerg Med 1996; 3: 271-273. [DOI:10.1111/j.1553-2712.1996.tb03432.x]
34. Wahdan MH. The Middle East: past, present and future. AIDS Asia 1995; 2: 21-23.
35. Gaydos CA, Howell MR, Pare B, Clark KL, Ellis DA, Hendrix RM, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998; 339: 739-744. [DOI:10.1056/NEJM199809103391105]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb